NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline. In addition to its clinical and commercial progress in GBM, it is planning or conducting clinical trials evaluating the use of TTFields in brain metastases, non-small-cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and mesothelioma. TTFields are delivered through a portable, medical device. The complete delivery system, which is designed to allow patients to go about their daily activities while receiving continuous cancer treatment, includes a portable electric field generator, transducer arrays, rechargeable batteries and accessories.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NVCR
CUSIPN/A
Phone44-0-15-3475-6700
Debt
Debt-to-Equity Ratio1.41
Current Ratio6.32
Quick Ratio5.87
Price-To-Earnings
Trailing P/E Ratio-44.43
Forward P/E Ratio-45.74
P/E GrowthN/A
Sales & Book Value
Annual Sales$177.03 million
Price / Sales15.93
Cash FlowN/A
Price / CashN/A
Book Value$1.27 per share
Price / Book24.49
Profitability
EPS (Most Recent Fiscal Year)($0.70)
Net Income$-61,660,000.00
Net Margins-33.12%
Return on Equity-56.70%
Return on Assets-23.65%
Miscellaneous
Employees495
Outstanding Shares90,700,000
Novocure (NASDAQ:NVCR) Frequently Asked Questions
What is Novocure's stock symbol?
Novocure trades on the NASDAQ under the ticker symbol "NVCR."
How were Novocure's earnings last quarter?
Novocure Ltd (NASDAQ:NVCR) posted its quarterly earnings results on Thursday, April, 26th. The medical equipment provider reported ($0.23) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.13) by $0.10. The medical equipment provider had revenue of $52.13 million for the quarter, compared to analyst estimates of $57.13 million. Novocure had a negative return on equity of 56.70% and a negative net margin of 33.12%. View Novocure's Earnings History.
When is Novocure's next earnings date?
What price target have analysts set for NVCR?
4 brokerages have issued 12 month target prices for Novocure's shares. Their predictions range from $19.00 to $33.00. On average, they expect Novocure's stock price to reach $28.00 in the next twelve months. View Analyst Ratings for Novocure.
What are Wall Street analysts saying about Novocure stock?
Here are some recent quotes from research analysts about Novocure stock:
- 1. Mizuho analysts commented, "We hosted a conference call with a at UCSF yesterday to discuss NovoCure’s Optune technology. We discussed adoption trends, patient compliance and the potential of Optune in cancer indications beyond glioblastoma (GBM). A few of our key takeaways are below." (6/13/2018)
- 2. According to Zacks Investment Research, "NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands. " (5/1/2018)
Who are some of Novocure's key competitors?
Some companies that are related to Novocure include Dexcom (DXCM), ICU Medical (ICUI), Hill-Rom (HRC), Insulet (PODD), Penumbra (PEN), Globus Medical (GMED), Haemonetics (HAE), Cantel Medical (CMD), NuVasive (NUVA), Merit Medical Systems (MMSI), Nevro (NVRO), Irhythm Technologies (IRTC), Glaukos (GKOS), Mazor Robotics (MZOR) and Luminex (LMNX).
Who are Novocure's key executives?
Novocure's management team includes the folowing people:
- Mr. William F. Doyle, Exec. Chairman (Age 56)
- Mr. Asaf Danziger, CEO & Director (Age 52)
- Mr. Kinyip Gabriel Leung, Vice Chairman & Chairman of the Global Commercialization Team (Age 56)
- Prof. Yoram Palti, Founder, CTO & Director (Age 80)
- Mr. Wilhelmus C. M. Groenhuysen, CFO & Principal Accounting Officer (Age 60)
Has Novocure been receiving favorable news coverage?
Media headlines about NVCR stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern scores the sentiment of media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Novocure earned a coverage optimism score of 0.18 on Accern's scale. They also gave news articles about the medical equipment provider an impact score of 47.89 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
Who are Novocure's major shareholders?
Novocure's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.16%), Baillie Gifford & Co. (3.03%), Farallon Capital Management LLC (2.04%), StepStone Group LP (1.51%), Tamarack Advisers LP (1.23%) and Frontier Capital Management Co. LLC (1.22%). Company insiders that own Novocure stock include Asaf Danziger, Charles G Phillips III, Eilon D Kirson, Gabriel Leung, Gert L Perlhagen, Michael J Ambrogi, Pomona Capital Vii Fund Invest, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen and Yoram Palti. View Institutional Ownership Trends for Novocure.
Which major investors are selling Novocure stock?
NVCR stock was sold by a variety of institutional investors in the last quarter, including StepStone Group LP, Millennium Management LLC, Cortina Asset Management LLC, Westfield Capital Management Co. LP, JPMorgan Chase & Co., A.R.T. Advisors LLC, Pier Capital LLC and BlackRock Inc.. Company insiders that have sold Novocure company stock in the last year include Asaf Danziger, Charles G Phillips III, Eilon D Kirson, Gabriel Leung, Michael J Ambrogi, Pomona Capital Vii Fund Invest, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen and Yoram Palti. View Insider Buying and Selling for Novocure.
Which major investors are buying Novocure stock?
NVCR stock was purchased by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., PointState Capital LP, Loomis Sayles & Co. L P, Farallon Capital Management LLC, Allianz Asset Management GmbH, Allianz Asset Management GmbH, Nuveen Asset Management LLC and California Public Employees Retirement System. View Insider Buying and Selling for Novocure.
How do I buy shares of Novocure?
Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Novocure's stock price today?
One share of NVCR stock can currently be purchased for approximately $31.10.
How big of a company is Novocure?
Novocure has a market capitalization of $2.90 billion and generates $177.03 million in revenue each year. The medical equipment provider earns $-61,660,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Novocure employs 495 workers across the globe.
How can I contact Novocure?
Novocure's mailing address is LE MASURIER HOUSE LA RUE LE MASURIER, ST. HELIER Y9, JE2 4YE. The medical equipment provider can be reached via phone at 44-0-15-3475-6700 or via email at [email protected]
MarketBeat Community Rating for Novocure (NVCR)
MarketBeat's community ratings are surveys of what our community members think about Novocure and other stocks. Vote "Outperform" if you believe NVCR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVCR will underperform the S&P 500 over the long term. You may vote once every thirty days.
